TriangleMAGENTA (NCT03081910)
MAGENTA trial for T-cell Acute Lymphoblastic Lymphoma (NCT03081910). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells transformed B-cell leukemia and lymphoma. For cancers of the T cells themselves, they have been almost impossible to build. The target sits on the weapon: a T cell built to kill anything carrying a T-cell marker kills its neighbors, and itself.
The idea: pick the one marker where that problem can be managed.
CD5 sits on about eighty-five percent of T-cell cancers. Baylor's team found that CAR T cells aimed at CD5 quickly shed their own CD5, so they stop attacking each other and keep hunting the cancer.
MAGENTA, at Houston Methodist and Texas Children's with Rayne Rouce, now makes the cells from a patient's earlier transplant donor, and asks what dose is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.